Skip to main content
Home ESG Stocks
Sanofi (SAN) Stock Analysis | ESG Ratings & Sustainability Insights
SAN.PA

Sanofi

Market Price
$357.16
24h Change
+1.27%
Market Cap
$16.08B
P/E Ratio
N/A

ESG & Sustainability Rating Breakdown

Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.

Audited Methodology

MSCI ESG Rating

A (Average)

MSCI ESG industry rating benchmark.

Sustainalytics Risk Score

18.8

Low

Sustainability Strengths & Catalysts (Pros)

  • Dupixent Blockbuster Success: Sanofi's Dupixent achieved €13 billion sales in 2024 with patent protection beyond 2031, targeting €22 billion by 2030, providing exceptional revenue visibility and growth runway.
  • Consistent Dividend Growth: The company offers 30 consecutive years of dividend increases with proposed €3.92 per share for 2024, demonstrating reliable shareholder returns and financial stability.
  • Strong Pipeline and Innovation: With 86 clinical-stage projects and 31 in Phase 3, launches contributed 11% of sales with new blockbuster Beyfortus, showcasing successful R&D execution and portfolio diversification.

Material Risks & Governance Concerns (Cons)

  • Pipeline Execution Risk: The recent itepekimab Phase 3 failure caused 6% stock decline, highlighting significant risks in replacing Dupixent revenues as competition approaches post-2031.
  • Pricing Pressure and Competition: Dupixent faces U.S. pricing pressures and emerging IL-13/JAK inhibitor competition, while Aubagio (€2 billion sales) loses patent protection imminently.

Company Profile & Business Model Overview

Financial & Valuation Fundamentals

Earnings Per Share (EPS)
$3.20
Dividend Yield
0.93%
Previous Close
$361.19
Day Open
$352.44

Data Integrity & Methodology Disclosure

Stock prices and market fundamentals are refreshed via our automated 04:00 UTC pipeline. ESG evaluations aggregate published ratings from MSCI ESG Research and Sustainalytics with normalized industry peer adjustments. Learn more in our ESG Rating Methodology.